Months after Hong Kong proposal, Stealth now seeking NASDAQ listing

Stealth BioTherapeutics Corp. (Newton, Mass.) proposed an IPO on NASDAQ late on Dec. 28, less than six months after filing to list on the Hong Kong stock exchange. The prospectus filed with the SEC on Dec. 28 does not mention a dual listing, and Stealth has yet to conduct a Hong Kong offering.

Stealth is developing therapies for diseases involving mitochondrial dysfunction. Its lead candidate, elamipretide, is a mitochondrial-targeting tetrapeptide that binds and stabilizes cardiolipin to promote electron transfer and prevent apoptosis...